参考文献/References:
[1]Xiang E,Han B,Zhang Q,et al.Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis[J].Stem Cell Res Ther,2020,11(1):336.[2]Witcher KG,Bray CE,Chunchai T,et al.Traumatic Brain Injury Causes Chronic Cortical Inflammation and Neuronal Dysfunction Mediated by Microglia[J].J Neurosci,2021,41(7):1597-1616.[3]Capitao M,Soares R.Angiogenesis and Inflammation Crosstalk in Diabetic Retinopathy[J].J Cell Biochem,2016,117(11):2443-2453.[4]Yuan Y,Yuan L,Li L,et al.Mitochondrial transfer from mesenchymal stem cells to macrophages restricts inflammation and alleviates kidney injury in diabetic nephropathy mice via PGC-1α activation[J].Stem Cells,2021,39(7):913-928.[5]Yiu WH,Wong DW,Wu HJ,et al.Kallistatin protects against diabetic nephropathy in db/db mice by suppressing AGE-RAGE-induced oxidative stress[J].Kidney Int,2016,89(2):386-398.[6]Sun MY,Wang SJ,Li XQ,et al.CXCL6 Promotes Renal Interstitial Fibrosis in Diabetic Nephropathy by Activating JAK/STAT3 Signaling Pathway[J].Front Pharmacol,2019,10:224.[7]Baer PC,Koch B,Geiger H.Kidney Inflammation,Injury and Regeneration[J].Int Mol Sci,2020,21(3):1164[8]Huang W,Man Y,Gao C,et al.Short-Chain Fatty Acids Ameliorate Diabetic Nephropathy via GPR43-Mediated Inhibition of Oxidative Stress and NF-κB Signaling[J].Oxid Med Cell Longev,2020:4074832.[9]Wang L,Zhang L,Yu Y,et al.The protective effects of taurine against early renal injury in STZ-induced diabetic rats,correlated with inhibition of renal LOX-1-mediated ICAM-1 expression[J].Ren Fail,2008,30(8):763-771.[10]Klessens CQF,Zandbergen M,Wolterbeek R,et al.Macrophages in diabetic nephropathy in patients with type 2 diabetes[J].Nephrol Dial Transplant,2017,32(8):1322-1329.[11]Zheng Z,Zheng F.Immune Cells and Inflammation in Diabetic Nephropathy[J].J Diabetes Res,2016,2016:1841690.[12]Landis RC,Quimby KR,Greenidge AR.M1/M2 Macrophages in Diabetic Nephropathy:Nrf2/HO-1 as Therapeutic Targets[J].Curr Pharm Des,2018,24(20):2241-2249.[13]Gottschalk C,Kurts C.The Debate about Dendritic Cells and Macrophages in the Kidney[J].Front Immunol,2015,6:435.[14]Wang R,Chen T,Wang C,et al.Flt3 inhibition alleviates chronic kidney disease by suppressing CD103+ dendritic cell-mediated T cell activation[J].Nephrol Dial Transplant,2019,34(11):1853-1863.[15]Taylor DK,Mittereder N,Kuta E,et al.T follicular helper-like cells contribute to skin fibrosis[J].Sci Transl Med,2018,10(431):aaf5307.[16]Herrera M,S?觟derberg M,Sabirsh A,et al.Inhibition of T-cell activation by the CTLA4-Fc Abatacept is sufficient to ameliorate proteinuric kidney disease[J].Am J Physiol Renal Physiol,2017,312(4):748-759.[17]Kim SM,Lee SH,Lee EA,et al.Targeting T helper 17 by mycophenolate mofetil attenuates diabetic nephropathy progression[J].Transl Res,2015,166(4):375-383.[18]Smith MJ,Simmons KM,Cambier JC.B cells in type 1 diabetes mellitus and diabetic kidney disease[J].Nat Rev Nephrol,2017,13(11):712-720.[19]Hara T,Ishida T,Cangara HM,et al.Endothelial cell-selective adhesion molecule regulates albuminuria in diabetic nephropathy[J].Microvasc Res,2009,77(3):348-355.[20]De Zeeuw D,Renfurm R W,Bakris G,et al.Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM):a randomised,placebo-controlled,phase 2 trial[J].Lancet Diabetes Endocrinol,2018,6(12):925-933.[21]Sayyed SG,Ryu M,Kulkarni OP,et al.An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes[J].Kidney Int,2011,80(1):68-78.[22]Navarro JF,Mora-Fernández C.The role of TNF-alpha in diabetic nephropathy:pathogenic and therapeutic implications[J].Cytokine Growth Factor Rev,2006,17(6):441-450.[23]Feigerlová E,Battaglia-Hsu SF.IL-6 signaling in diabetic nephropathy:From pathophysiology to therapeutic perspectives[J].Cytokine Growth Factor Rev,2017,37:57-65.[24]Yaribeygi H,Atkin SL,Sahebkar A.Interleukin-18 and diabetic nephropathy:A review[J].J Cell Physiol,2019,234(5):5674-5682.[25]Wada J,Makino H.Innate immunity in diabetes and diabetic nephropathy[J].Nat RevNephrol,2016,12(1):13-26.[26]Zhu X,Shi J,Li H.Liquiritigenin attenuates high glucose-induced mesangial matrix accumulation,oxidative stress,and inflammation by suppression of the NF-κB and NLRP3 inflammasome pathways[J].Biomed Pharmacother,2018,106:976-982.[27]Kim JE,Lee MH,Nam DH,et al.Celastrol,an NF-κB inhibitor,improves insulin resistance and attenuates renal injury in db/db mice[J].PLoS One,2013,8(4):e62068.[28]Vallon V,Gerasimova M,Rose MA,et al.SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice[J].Am J Physiol Renal Physiol,2014,306(2):194-204.[29]丁鑫,许灿坤,姬燕,等.达格列净与沙格列汀对老年2型糖尿病患者炎症指标和肾功能的影响[J].中华老年多器官疾病杂志,2022,21(2):115-119.[30]Hiruma S,Shigiyama F,Hisatake S,et al.A prospective randomized study comparing effects of empagliflozin to sitagliptin on cardiac fat accumulation,cardiac function,and cardiac metabolism in patients with early-stage type 2 diabetes:the ASSET study[J].Cardiovasc Diabetol,2021,20(1):32.[31]Heerspink HJL,Perco P,Mulder S,et al.Canagliflozin reduces inflammation and fibrosis biomarkers:a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease[J].Diabetologia,2019,62(7):1154-1166.[32]王媛媛,李惠莉,李元梅,等.西格列汀对2型糖尿病肾病2期患者的影响[J].浙江实用医学,2018,23(3):176-179.[33]Muskiet MHA,Tonneijck L,Smits MM,et al.GLP-1 and the kidney:from physiology to pharmacology and outcomes in diabetes[J].Nat Rev Nephrol,2017,13(10):605-628.
相似文献/References:
[1]黄德斌,章臻翊,章 婷,等.2型糖尿病患者亚临床甲状腺功能减退与白蛋白尿的关系研究[J].医学信息,2018,31(02):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
HUANG De-bin,ZHANG Zhen-yi,ZHANG Ting,et al.Relationship between Subclinical Hypothyroidism and Albuminuria in
Patients with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2018,31(01):88.[doi:10.3969/j.issn.1006-1959.2018.02.030]
[2]邓婷婷,王亚洲,张 红.口福怡稻治疗2型糖尿病的临床效果研究[J].医学信息,2018,31(03):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
DENG Ting-ting,WANG Ya-zhou,ZHANG Hong.Clinical Study on the Treatment of Type 2 Diabetes Mellitus with Kou Fuyi Dao[J].Journal of Medical Information,2018,31(01):116.[doi:10.3969/j.issn.1006-1959.2018.03.039]
[3]曹岚,侯瑞田,王福慧,等.Lp-PLA2血小板相关因子与2型糖尿病合并高血压病的
相关性研究[J].医学信息,2018,31(05):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
CAO Lan,HOU Rui-tian,WANG Fu-hui,et al.Study on the Correlation between Lp-PLA2 Platelet-associated Factors and Type 2 Diabetes Mellitus Complicated with Hypertension[J].Journal of Medical Information,2018,31(01):3.[doi:10.3969/j.issn.1006-1959.2018.05.002]
[4]陈淑雯.肾衰宁联合科素亚治疗早期糖尿病肾病的临床观察[J].医学信息,2018,31(05):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
CHEN Shu-wen.Clinical Observation on Early Diabetic Nephropathy Treated by Shenshuaining Combined with Kosu[J].Journal of Medical Information,2018,31(01):20.[doi:10.3969/j.issn.1006-1959.2018.05.007]
[5]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(01):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[6]刘 洪.地特胰岛素或甘精胰岛素联合使用口服药物治疗2型糖尿病疗效及对体重的影响分析[J].医学信息,2018,31(09):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
LIU Hong.Effect of Insulin Detemir or Insulin Glargine Combined with Oral Medication on Type 2 Diabetes Mellitus and its Influence on Body Weight[J].Journal of Medical Information,2018,31(01):135.[doi:10.3969/j.issn.1006-1959.2018.09.042]
[7]何丽杰.中西医治疗糖尿病肾病的临床效果分析[J].医学信息,2018,31(10):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
HE Li-jie.Clinical Effect Analysis of Diabetic Nephropathy Treated by Chinese and Western Medicine[J].Journal of Medical Information,2018,31(01):149.[doi:10.3969/j.issn.1006-1959.2018.10.051]
[8]郭云飞,王亚柱,刘 超,等.血浆致动脉硬化指数与冠心病合并2型糖尿病的相关性分析[J].医学信息,2022,35(09):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
GUO Yun-fei,WANG Ya-zhu,LIU Chao,et al.Correlation Between Plasma Arteriosclerosis Index and Coronary Heart Disease Complicated with Type 2 Diabetes Mellitus[J].Journal of Medical Information,2022,35(01):108.[doi:10.3969/j.issn.1006-1959.2022.09.027]
[9]徐晨曦.达格列净联合DPP-4抑制剂与二甲双胍对血糖控制不佳2型糖尿病患者血糖及脂代谢的影响[J].医学信息,2022,35(09):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
XU Chen-xi.Effects of Daglitazone Combined with DPP-4 Inhibitor and Metformin on Blood Glucose and Lipid Metabolism in Patients with Type 2 Diabetes Mellitus with Poor Glycemic Control[J].Journal of Medical Information,2022,35(01):165.[doi:10.3969/j.issn.1006-1959.2022.09.042]
[10]贺 伟,高 峰.24 h尿微量白蛋白、血清胱抑素C水平与血清肌酐、尿素水平在2型糖尿病肾病早期诊断的意义[J].医学信息,2018,31(11):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
HE Wei,GAO Feng.The Significance of 24 h Urinary Microalbumin,Serum Cystatin C and Serum Creatinine and Urea Levels in the Early Diagnosis of Type 2 Diabetic Nephropathy[J].Journal of Medical Information,2018,31(01):151.[doi:10.3969/j.issn.1006-1959.2018.11.049]
[11]李 娟,冯双双,康京京,等.尿β2微球蛋白水平与2型糖尿病患者视网膜病变和肾脏病变的相关性[J].医学信息,2020,33(19):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
LI Juan,FENG Shuang-shuang,KANG Jing-jing,et al.Correlation Between Urine β2 Microglobulin Level and Retinopathy and Nephropathy in Type 2 Diabetic Patients[J].Journal of Medical Information,2020,33(01):99.[doi:10.3969/j.issn.1006-1959.2020.19.029]
[12]赵 慧,巩林霞,魏兆丽,等.脂质代谢指标在2型糖尿病肾病中的表达水平及与尿白蛋白的相关性[J].医学信息,2022,35(16):109.[doi:10.3969/j.issn.1006-1959.2022.16.026]
ZHAO Hui,GONG Lin-xia,WEI Zhao-li,et al.Expression of Lipid Metabolism Indexes in Type 2 Diabetic Nephropathy and its Correlation with Urinary Albumin[J].Journal of Medical Information,2022,35(01):109.[doi:10.3969/j.issn.1006-1959.2022.16.026]
[13]李 盈,李 涛,王 潇,等.利用SPECT影像技术评估糖尿病视网膜病变与糖尿病肾病的相关性[J].医学信息,2024,37(05):108.[doi:10.3969/j.issn.1006-1959.2024.05.018]
LI Ying,LI Tao,WANG Xiao,et al.Correlation Between Diabetic Retinopathy and Diabetic Nephropathy by SPECT Imaging Technique[J].Journal of Medical Information,2024,37(01):108.[doi:10.3969/j.issn.1006-1959.2024.05.018]